We have reported the crystal structure of human serum albumin (HSA) at a resolution of 6.0 A by the method of multiple isomorphous replacement (1) . A different quaternary arrangement of the six subdomains than that reported at low resolution has become apparent at 4 A resolution (2). The change in the electron density involves connecting the previously labeled aminoand carboxyl-terminal helices through the symmetry operation (Y, X, 1-Z) together with a concomitant formation of new termini (Fig. IA) . This connection was not revealed in the electron density at 6.0 A mainly because of series termination effects that are usually more pronounced at lower resolution. The attachment of the tail (subdomains IIB, IIIA, and IIIB) to the head (subdomains IA, IB, and IIA) of the molecule differs from that originally proposed and requires relabeling of certain subdomains (Fig. 1B) . Further evidence supports this quaternary arrangement. The subdomains assume a heart shape, which agrees with the dark-field electron micrograph images of the genetically related human and bovine cx-fetoproteins (AFP) (3). Domains I, II, and III may be superimposed (Fig.  IC) , which is consistent with the homology within the amino acid sequence. The major ligand binding regions are identified within subdomains IIA (previously labeled IA) and IIIA, which is consistent with the competitive drug displacement experiments (4) and Deprenyl and the Progression of Parkinson's Disease
In the report by James W. Tetrud and J. William Langston on "The effect of deprenyl (Selegiline) on the natural history of Parkinson's disease" (1), the authors conclude that deprenyl treatment retards the progression of Parkinson's disease. They say they arrive at this conclusion because they found that a group of placebo-treated patients required L-dopa treatment sooner than a group ofdeprenyl-treated subjects; however these investigators assessed the apparent severity of the illness while the patients in the deprenyl group were receiving deprenyl. Thus one group was receiving treatment with a monoamine oxidase inhibitor, which increases dopamine levels in the brain, while the other group was receiving no active treatment at the time of the assessment.
It seems quite probable that the deprenyl group would appear to have progressed less compared to the placebo group simply because they were receiving deprenyl and thus displaying fewer symptoms. The authors attempt to deal with this possible confounding factor by showing that at the time the deprenyl group required L-dopa for symptom control, they did not get worse when the deprenyl was discontinued. This, however, is not an adequate demonstration that deprenyl was not producing therapeutic benefits at earlier assessment points when the Parkinson's was less severe (that is, when the deprenyl group appeared to have an advantage over the placebo group).
In order for Tetrud and Langston to have correctly arrived at their conclusions, the subjects should have been withdrawn from deprenyl at each assessment point and the assessment carried out after deprenyl washout, so that Parkinson's status could have been assessed in an untreated state. Alternatively the placebo group could have been treated with deprenyl before each assessment so that the same level of monoamine oxidase inhibition could be achieved in each group. 20 JULY 1990 In the absence of a comparable assessment of the two groups it is not justifiable to conclude that deprenyl retards the progression of Parkinson's disease, however attractive this possibility is from a theoretical standpoint. symptomatic effect ofdeprenyl, rather than a slowing of the disease process, could account for the results of our study. As pointed out by Sudarsky, since deprenyl is an inhibitor of monoamine oxidase, it might increase the synaptic persistence of endogenously released dopamine, thereby leading to some degree of symptomatic improvement. To assess this possibility, two steps were taken in our study. First, patients were carefilly reevaluated 1 month after the study drug was started to see if they had improved compared to their baseline evaluation (this would have indicated a symptomatic effect). At this 1-month "wash-in" evaluation, no
